Add Formweb to your mobile device
Search results for:
aprepitant
aprepitant
Brand names: Cinvanti, Emend
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPSULE, ORAL | 40 mg; 80 mg; 125 mg | Restricted | ||||||||||
| EMULSION, INTRAVENOUS | 130 mg/18 mL | Restricted | ||||||||||
| POWDER FOR RECONSTITUTION, ORAL | 125 mg | Restricted |
Last updated: Nov. 16, 2023
- Restricted: aprepitant (Emend) oral - is restricted to use by medical oncologists for the prevention of acute and delayed emesis for moderately or highly emetogenic chemotherapy
- Restricted: aprepitant (Cinvanti) is restricted to use in the Outpatient setting by Hem/Onc only
Emetogenic Potential of Intravenous Antineoplastic Agents (NCCN Antiemesis Guidelines - Updated May 24, 2023)
High emetic risk (>90% frequency of emesis)
• AC combination defined as any chemotherapy regimen that contains an anthracycline and
cyclophosphamide
• Carboplatin AUC ≥4
• Carmustine >250 mg/m2
• Cisplatin
• Cyclophosphamide >1500 mg/m2
• Dacarbazine
• Doxorubicin ≥60 mg/m2
• Epirubicin >90 mg/m2
• Fam-trastuzumab deruxtecan-nxki
• Ifosfamide ≥2 g/m2
per dose
• Mechlorethamine
• Melphalan ≥140 mg/m2
• Sacituzumab govitecan-hziy
• Streptozocin
Moderate emetic risk (>30-90% frequency of emesis)
• Aldesleukin >12–15 million IU/m2
• Amifostine >300 mg/m2
• Bendamustine
• Busulfan
• Carboplatin AUC <4*
• Carmustine ≤250 mg/m2*
• Clofarabine
• Cyclophosphamide ≤1500 mg/m2*
• Cytarabine >200 mg/m2
• Dactinomycin*
• Daunorubicin*
• Dinutuximab
• Doxorubicin <60 mg/m2*
• Dual-drug liposomal encapsulation
of cytarabine and daunorubicin
• Epirubicin ≤90 mg/m2*
• Idarubicin*
• Ifosfamide <2 g/m2 per dose*
• Irinotecan*
• Irinotecan (liposomal)
• Lurbinectedin
• Melphalan <140 mg/m2
• Methotrexate ≥250 mg/m2*
• Naxitamab-gqgk
• Oxaliplatin*
• Romidepsin
• Temozolomide
• Trabectedin*
*These agents may be highly emetogenic in certain patients.